Clinical Trials on Hematological Diseases in Australia

Total 13411 results

Pfizer
Pfizer

Completed

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

Sickle Cell Disease

Australia, United States
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders. (EMBRACE)

Aplastic Anemia | Bone Marrow Failure Syndrome

Australia
AOP Orphan Pharmaceuticals AG

Completed

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)

Polycythemia Vera

Austria
Austin Health

Unknown

"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery

Myocardial Ischemia | Coronary Artery Disease | Blood Coagulation Disorders | Heart Valve Diseases

Australia
Hoffmann-La Roche

Terminated

A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.

Anemia

Australia
Blueprint Medicines Corporation
Analysis Group, Inc.

Completed

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological Neoplasm

United States, Austria, Germany, Spain, United Kingdom
Novo Nordisk A/S

Completed

Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

Australia
Hoffmann-La Roche

Completed

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Anemia

Australia
Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
Otsuka Australia Pharmaceutical Pty Ltd

Completed

Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire (TPMQ)

Myelodysplastic Syndrome (MDS)

Australia
Eupraxia Pharmaceuticals Inc.

Recruiting

A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE). (RESOLVE)

Eosinophilic Esophagitis

Australia, Canada, Netherlands
Clinuvel Pharmaceuticals Limited

Completed

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

Polymorphic Light Eruption (PLE)

Austria, Australia, United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

Influenza

Australia, Singapore
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
Seqirus

Completed

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Influenza

Australia
Azora Therapeutics Australia Pty Ltd

Completed

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Australia
EpiAxis Therapeutics
The Canberra Hospital; Southern Medical Day Care Centre; Liverpool Cancer Therapy...

Completed

An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer (Epi-PRIMED)

Metastatic Breast Cancer

Australia
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Polycythemia Vera

United States, Canada, Italy, Australia
Bayside Health

Terminated

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Murdoch Childrens Research Institute

Recruiting

Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (ELSA-FN)

Febrile Neutropenia

Australia
Peter MacCallum Cancer Centre, Australia
Melbourne Health

Completed

NMP in Relapsed / Refractory Myeloma

Multiple Myeloma

Australia
Bayside Health

Unknown

Atorvastatin in Myeloma

Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone

Lymphoma | Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation; Janssen-Cilag Ltd.

Unknown

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Janssen-Cilag Ltd.

Completed

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Multiple Myeloma

Australia
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Spain, Australia, Denmark, Norway
Silence Therapeutics plc

Recruiting

Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)

Polycythemia Vera

United States, Australia, Malaysia, Bulgaria, Poland
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
Cancer Trials Australia
Human Genome Sciences Inc.

Unknown

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Symptomatic Waldenstroms Macroglobulinaemia

Australia
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; Boehringer... and other collaborators

Completed

Can Resistance Enhance Selection of Treatment? (CREST)

HIV Infection

Australia
Medical University of Vienna

Completed

Hepcidin in Anemic Chronic Heart Failure (CHF) Patients

Anemia | Chronic Heart Failure

Austria
Peter MacCallum Cancer Centre, Australia
National Health and Medical Research Council, Australia; University of Melbourne

Recruiting

Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) (IBMDx)

Hematologic Diseases | Inherited Platelet Disorder | Inherited BMF Syndrome

Australia
GlaxoSmithKline

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Infections, Meningococcal

Australia
AbbVie

Withdrawn

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Multiple Myeloma

Australia
Ellipses Pharma

Recruiting

Study to Evaluate the Safety and Tolerability of EP0042

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia, Netherlands, United Kingdom
Bayside Health

Completed

Efficacy Study of Outpatient Therapy for Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

Australia
Celgene

Completed

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Melanoma | Lymphoma | Multiple Myeloma | Pancreatic Cancer | Non-Small Cell Lung Cancer

Australia
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
Novartis Pharmaceuticals

Completed

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Bone Neoplasms

Australia
Vyne Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Australia
Centre Hospitalier Universitaire Vaudois

Unknown

Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI) (BIMI)

Hematologic Diseases | Hematologic Malignancy | Invasive Mold Infections | Breakthrough Invasive Mold Infections

Switzerland, Austria, Germany
South Eastern Sydney Local Health District
GlaxoSmithKline

Unknown

The International ITP Registry

Thrombocytopenia

Singapore, Korea, Republic of, Thailand, Turkey, Australia, Colombia, Kuwait, Malaysia, Taiwan, Uruguay
The University of Queensland

Recruiting

The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

Pulmonary Fibrosis | Dyskeratosis Congenita | Telomere Shortening | Telomere Disease

Australia
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland

Clinical Trials on Hematological Diseases in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations